Partnering with DiaGenic
Our goal is to provide diagnostic solutions to meet unmet needs within Alzheimer’s disease. Excellence in Research and Developement is our heritage, whether we develop products on our own or with partners. We have a proven track record with Pfizer on research collaboration where DiaGenic (i) identified patients who progress from MCI to Alzheimer dementia onset within 24 months, and (ii) identified gene signatures to monitor disease progression. In addition DiaGenic has entered a research agreement with GE Healthcare to for brain amyloid detection.
DiaGenic is actively pursuing additional non-exclusive R&D collaborations with key industry players to develop its technology, investigate future strategic partnerships and commercial channels, as well as opportunities within companion diagnostics (CDx).
We invite you to contact us to explore possible ways we may combine our individual strengths to bring new technologies to the market.